Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• BCR/ABL1 fusion protein drives chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (Ph1-ALL) by promoting cell proliferation and genomic instability.
• BCR/ABL1 downregulates BRCA1, creating a vulnerability in cancer cells.
• PARP inhibitors (PARPi) induce cell death in BRCA-deficient cells.

Purpose of the Study:

• To investigate the efficacy of PARP inhibitors (PARPi) in treating BCR/ABL1-positive leukemias.
• To evaluate the potential of PARPi, specifically olaparib, in preclinical models of BCR/ABL1-mediated leukemia.
• To explore the underlying mechanisms of PARPi action in leukemia, including interferon signaling.

Main Methods:

• In vitro studies assessing PARPi-induced cell death and colony formation in BCR/ABL1-positive cells.
• In vivo studies using mouse models: hematopoietic cell transplantation and genetically engineered mice (Parp1 knockout x BCR/ABL1 transgenic).
• Analysis of interferon signaling pathways, including cGAS/STING activation.

Main Results:

• PARPi effectively induced cell death and suppressed colony formation in BCR/ABL1-positive leukemia cells.
• Olaparib demonstrated attenuation of BCR/ABL1-mediated leukemogenesis in both in vivo models.
• PARPi treatment was associated with increased interferon signaling via the cGAS/STING pathway.

Conclusions:

• PARPi are a promising therapeutic strategy for BCR/ABL1-positive leukemias due to BRCA1 downregulation.
• Olaparib shows preclinical efficacy in inhibiting BCR/ABL1-driven leukemogenesis.
• Combination therapy with PARPi and tyrosine kinase inhibitors (TKIs) may offer a more effective approach to eradicate CML stem cells.